Excerpt
This work is partly a response to NIHCE guidance which recommended LVEF assessment prior to recruitment and also for ongoing monitoring for cardio-toxicity during Herceptin treatment. The guideline recommend an LVEF cut-off of 55% for entry to treatment and that treatment should be discontinued if the LVEF dropped below 50% or dropped by more than 10% from baseline.
As part of this process, what we aim to achieve is to:
The way in which we plan to achieve this is that:
We hope that this will yield results in the short and also the medium term:
If your centre performs a large number of MUGA and you have a little energy and time to put in to this project, you could help us by applying to become one of the reference sites. Contact BNMS: office@bnms.org.